Imported Talaromycosis in Oman in Advanced HIV: A Diagnostic Challenge Outside the Endemic Areas by Mohsin, J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/177603
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Imported Talaromycosis in Oman in Advanced HIV:
A Diagnostic Challenge Outside the Endemic Areas
Jalila Mohsin . Sulin Al Khalili . A. H. G. Gerrits van den Ende .
Faryal Khamis . Eskild Petersen . G. Sybren de Hoog .
Jacques F. Meis . Abdullah M. S. Al-Hatmi
Received: 22 January 2017 / Accepted: 21 February 2017 / Published online: 4 March 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract A 37-year-old male living in Oman was
seen by his physician with complaints of cough, body
aches with bilateral lower limb weakness and on and
off fever. He was diagnosed with HIV infection and
culture from blood and bone marrow grew Talar-
omyces marneffei. He had travelled to Malaysia on
several occasions. Treatment with liposomal ampho-
tericin B resulted in complete cure. This case is
reported for its rarity and unusual presentation to alert
clinicians and microbiologists to consider T. marneffei
as an etiology in high risk individuals. Our case is the
first recorded diagnosis of T. marneffei in Oman.
Keywords Talaromyces marneffei  Talaromycosis 
Penicillium marneffei  Penicilliosis  HIV  Travel-
related infections  Oman
Background
Talaromyces marneffei (formerly Penicillium marn-
effei) [1] is a facultative intracellular pathogen capable
of causing disseminated infections in humans with
wild bamboo rats in Southeast Asia as the natural
reservoir [2, 3]. The first case of talaromycosis was
reported in 1973 from an American minister who had
Hodgkin’s disease and been living in Southeast Asia
[4]. In 1984, the second reported case also concerned
an American citizen, who had travelled in Thailand
[5]. Four years later, T. marneffei was identified in
HIV-infected individuals [6], and soon it emerged as
an AIDS-defining disease in endemic regions [7].
Talaromycosis has become an important risk to
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immunocompromised travelers with impaired
acquired immunity to these regions, particularly
Vietnam, Laos, Malaysia, Myanmar, East India,
Thailand and the Guang Xi province in southeastern
China. Numerous cases of talaromycosis have been
described in patients with a latently compromised
immune system returning from these endemic areas
[8], but also in organ transplant recipients from donors
originating from these regions [9].
Patients usually present with fungal invasion of
multiple organ systems such as blood, bone marrow,
skin and lungs [10]. Talaromyces marneffei infection
has a high mortality, when diagnosis and treatment are
delayed. Mostly, cases of talaromycosis are seen in
patients having CD4 T-lymphocyte cell counts
\100 cells/mL [11]. Although the vast majority of
patients with talaromycosis are HIV-infected, T.
marneffei infection has been documented among
patients with other types of impaired cell-mediated
immunity [2].
With increasing international travel, T. marneffei is
becoming a threat to tourism to the tropics. Imported
cases of this mycosis to theMiddle East have as yet not
been reported. To the best of our knowledge, our case
from the Middle East is the first example of dissem-
inated T. marneffei infection in an HIV-diagnosed
patient who visited an endemic area.
Case Report
A 37-year-old male was admitted on the June 4, 2016,
at a secondary care hospital in Oman with a history of
anorexia, significant weight loss of 30 kg over a period
of 5 weeks, generalized body pain with bilateral lower
limb weakness and periodic fever. Blood cultures were
initially reported negative. Preliminary investigations
for pyrexia of unknown origin, and blood and urine
cultures and serology for Brucella and Q-fever were
negative. However, human immunodeficiency virus
(HIV-1&2) testing by a fourth generation enzyme-
linked immunosorbent assay (ELISA) turned out to be
positive.
Four days post-admission, the patient developed a
generalized, vesicular, non-umbilicated rash over
face, arms, trunk front and back and both legs
clinically suggestive of chickenpox, which was treated
with intravenous acyclovir. Unfortunately, no samples
were taken from the skin lesions or from blood to
confirm this infection. In the third week of admission,
he was transferred to the Royal Hospital, a tertiary
health care facility for additional investigations and
management. He had a history of traveling toMalaysia
several times for reasons that were unrevealed; the
latest was 2 months prior to his admission lasting
10 days. He denied any contact with animals including
rats.
The patient complained of bilateral lower limb
pain, numbness and weakness. He was fully awake and
had preserved patellar and achilles reflexes and down-
going planters (negative Babinski). He had crusted,
dry, papulo-macular skin lesions in the face, head and
extremities (Fig. 1a, b). He was not in distress and had
no jaundice or palpable lymphadenopathy. Physical
examination showed that the patients was emaciated,
pale and depressed, with temperature of 38.1 C. The
Glasgow Coma Scale (GCS) was 15/15 without
slurred speech but with weak wasted limbs. He also
had oral candidiasis which is one of the indicators for a
possible HIV infection. Computed Tomography (CT)
of the brain was suggestive of minimal periventricular
white matter hypodensity, crowding of the gyri with
obliteration of the CSF spaces at the convexity of the
brain, while a chest CT showed significant mediastinal
and hilar adenopathy as well as a right lower lobe
intra-parenchymal lymph node. An ill-defined, small
ground-glass opacity was seen in the right middle lobe
of lung. An abdominal CT showed splenomegaly with
mild hepatomegaly. The radiological differentials
included tuberculosis, lymphoma or reactive adenopa-
thy related to HIV infection. A nerve conduction study
showed an acute distance dependent axonal sensori-
motor polyneuropathy consistent with chronic sym-
metrical polyneuropathy. The patient refused a lumbar
puncture and MRI.
Laboratory Investigations
Laboratory results revealed low hemoglobin (9.6 g/
dl), thrombocytopenia (52 9 109/L), leukocytopenia
(1.1 9 109/L) with neutrophilia (0.7 9 109/L) and
lymphocytopenia (0.3 9 109/L). Blood film showed
pancytopenia and low CD4 count of 100 cells/lL and
an elevated C-reactive protein of 66 mg/L. Serological
tests for hepatitis-B and hepatitis-C viruses and
syphilis were negative. HIV-1 was confirmed by
immunoblot determining the viral load as 1,754,540
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Fig. 1 a, b Figs. 1 and 2: crusted dry skin lesions over forehead
and left tibia. c, d Growth of the isolate T. marneffei on SAB
agar, front white yeast-like growth and the reverse is light
brownish after 3 d. e, cWhite greenish centered powdery fungal
colonies with distinctive red diffusible pigment on Sabouraud’s
dextrose agar, consistent with the characteristics of T. marneffei.
g Gram stain of the initial fungal growth at 37 C with
arthroconidia. h , i Conidiophores. Scale bar: 10 lm. (Color
figure online)
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copies/mL (log10 of 6.24). Serum galactomannan was
positive, but beta-D-glucan was not done. The patient
was started initially on fluconazole 400 mg once daily
on day 4 of admission (21/6/16) for oral candidiasis.
ATRIPLA (Efavirinz 600 mg, Emtricitiabine 200 mg
and Tenofovir 300 mg) and Pneumocystis jirovecii
prophylaxis (960 mg co-trimoxazole thrice a week)
was started on day 17 of admission (3/7/16). No
immune reconstitution syndrome was observed.
Blood cultures became positive after 72 h of
incubation. The initial Gram stain was negative, while
aerobic subcultures were positive on blood, chocolate
blood agar, MacConkey agar and Sabouraud’s glucose
agar after 48 h at 37 C. Gram stain showed hyaline,
septate hyphae that had the appearance of arthroconi-
dia (Fig. 1g). All microbiological processing of the
isolate was done under biosafety level 3 (BSL-3)
containment. Examination of Sabouraud’s plates
incubated at 25 C after 24 h showed light green,
powdery fungal colonies with a red diffusible pigment
and a red colony reverse (Fig. 1e, f). Lactophenol
cotton blue staining for microscopy revealed fruiting
structures and spherical conidia suggestive of Peni-
cillium/Talaromyces species (Fig. 1h, i). Subsequent
blood cultures, to verify its significance, taken on day
6 of admission, grew the same pathogen after 72 h of
incubation. Re-examination of the SGA plates at
37 C after 72 h of incubation showed wrinkled,
convoluted pink to red colonies with a non-diffusible
red pigment (Fig. 1c, d). The patient also underwent a
bone marrow aspiration (BMA), done on day 9 of
admission in view of pancytopenia. Further staining
with Periodic acid-Schiff (PAS) and GMC revealed no
fungal elements.Mycobacterium tuberculosis cultures
remained negative. A BMA sample was also sent for
microbiological culturing and showed similar fungal
growth as in the blood culture. There were no sputum
or BAL specimens submitted for cytology or routine
bacteriology and mycology cultures.
In view of the above microbiological findings,
symptoms and a history of travel to Southeast Asia, the
possibility of Talaromyces (Penicillium) marneffei
infection was suspected. Therapy was initiated with
liposomal amphotericin B 200 mg on day 9 of
admission (26/6/16) that was continued for 1 week
then shifted to oral voriconazole 200 mg twice daily
after a loading dose that was given for a total of
2 weeks. He started also, as per the neurology team
advice, on low-dose amitriptyline (20 mg at night)
plus gabapentin (1000 mg per day) to control his
neuropathic pain. The inflammatory markers
decreased during treatment: C-reactive protein: (17/
6: 66), (22/6: 26), (2/7: 11) and (12/7: 3). Neutrophils:
(17/6: 0.7), (20/6: 0.8), (27/6: 2.9) and (2/7: 3.3). The
patient was discharged on 4/7/16. One week after
discharge, he was seen at the outpatient clinic, and
repeated blood culture was subsequently negative.
There was an excellent response to the therapy.
Further identification of the fungus was undertaken
at the Westerdijk Fungal Biodiversity Institute in
Utrecht, The Netherlands, under accession number
CBS 141765. Sequencing of the rDNA internal
Fig. 2 Phylogenetic tree of Talaromyces section (representative
of type strains of closely related species to T. marneffei) inferred
from ITS based on maximum likelihood analysis. Bootstrap
values above 50% are indicated at the nodes. Our strain is
indicated with red color. (Color figure online)
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transcribed spacer region (ITS) and the partial b-
tubulin (BT2) gene was performed. Blast results with
sequences in GenBank with ITS revealed 100%
identity with T. marneffei (accession No.
AB353910.1) and with b-tubulin 100% identity with
T. marneffei (accession No. JX091389.1). Sequences
of this human pathogen (CBS 141765) were deposited
in GenBank with accession numbers KY115196 for
ITS and KY115197 for BT2, respectively. Antifungal
susceptibility testing performed with broth microdi-
lution according to CLSI M38A resulted in the
following MICs: amphotericin B, 0.25 mg/L; flucona-
zole, 4 mg/L; posaconazole,\0.016 mg/L; itracona-
zole, 0.031 mg/L; voriconazole and isavuconazole,
0.016 mg/l; and both anidulafungin and micafungin,
0.031 mg/L.
Discussion
Talaromycosis is a disseminated infection caused by
the fungus Talaromyces (Penicillium) marneffei. The
disease has been reported in immunocompromised but
occasionally also in otherwise healthy hosts [12].
Infection with T. marneffei is an endemic disease in
patients with T cell immunodeficiency in Southeast
Asia especially Northern Thailand, Vietnam and
southern China, but extending to Taiwan, Singapore,
Malaysia, Indonesia and India [13]. Locally acquired
infections outside these endemic areas are extremely
rare. One case was reported from West Africa in an
HIV-positive patient originating from Ghana who had
never travelled to tropical Asia [14]. Cases among
Africans who have travelled to endemic countries [8]
are much more common. Talaromycosis in HIV-
positive individuals may occur when CD4 counts fall
below 100 cells/lL. Most common symptoms of
talaromycosis are fever, weight loss, lymphadenopa-
thy, nonproductive cough, hepatosplenomegaly and
anemia. Many patients present with multiple papular
skin lesions in the face, neck, trunk and upper limbs.
About one third of patients have a cough and
pulmonary symptoms [15]. The mode of infection of
T. marneffei is unclear, as the only established hosts
are bamboo rats (Rhizomys and Cannomys spp.) and
humans [16], and host-to-host transmission is not
known to occur.
Determination of whether a patient has visited an
area of endemicity is essential for rapid diagnosis of T.
marneffei. The present case describes clinical and
mycological findings of the first imported case of
Talaromyces marneffei to Oman and the Middle East.
The patient was initially clinically diagnosed as
having a Varicella Zoster Virus (VZV) infection,
which was, however, not verified. The patient had HIV
infection with very low CD4 counts and typical skin
lesions suggestive of T. marneffei.
Diagnosis of talaromycosis is usually achieved by
staining, culture, serologic and molecular methods.
Final confirmation is obtained by histopathology of
intracellular arthroconidia and culture. Talaromyces
marneffei can be observed in histopathological sec-
tions stained with hematoxylin and eosin, Grocott
methenamine silver, or periodic acid-Schiff stain [12].
The organism also can be identified on peripheral
blood smear or bone marrow aspirate [17]. Blood
cultures are frequently positive, while bone marrow
cultures are positive in nearly all cases [17].
The fungus grows as a mold at room temperature
and converts to a ‘yeast-like’ (arthroconidial) form
when incubated at 37 C. This dimorphism is not
found in any other member of the genus Talaromyces,
which contains numerous penicillium-like species
with colonies that exude red pigments into the agar
[18, 19]. The fungus was initially misidentified as
Geotrichum or Trichosporon because of the arthro-
conidia in the Gram stain of slides taken at 37 C.
Final diagnosis of the case as disseminated T. marn-
effei infection was made by presence of the arthro-
conidia, growth of the fungus from BMA and blood
and by molecular identification of the pathogen as
Talaromyces (Penicillium) marneffei.
The clinical outcome of talaromycosis can be fatal
if it remains undiagnosed and untreated. Among HIV-
infected patients with low CD4 counts, talaromycosis
is an AIDS-defining diagnosis [20]. Additional cuta-
neous manifestations of translucent papular lesions,
umbilicated with a central necrotic depression at the face
and extremities characterizing talaromycosis [21], were
also presented in our patient. Such lesions are similar to
those observed in other fungal infections, particularly
cryptococcosis and histoplasmosis, and were recently
also reported from Emergomyces africanus infections
[22, 23]. However, the occurrence of these skin lesions in
the context of fever, cough, dyspnea, weight lost, fatigue
and the presence of arthroconidia, with the evidence of
patient’s travel history to an endemic area, suggested
infection by T. marneffei.
Mycopathologia (2017) 182:739–745 743
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The infection is limited to Southeast Asia. Excep-
tional autochthonous T. marneffei infections have
been reported in other parts of the world such as Ghana
and Togo in Africa [14, 21]. In China, prevalence of T.
marneffei infections ranged from 1.4 to 9.4%, with
reports from Beijing, 1.4% from 2009 to 2012 in HIV
infection, Wuhan, Hubei 4.8% of AIDS-related hos-
pital admission from (2006 to 2013) and 9.4% of HIV-
positive patients in Guangzhou from (2004 to 2011)
[24]. Patients with AIDS and talaromycosis present all
over the world and mostly following travel history.
Hence, a detailed travel history is important in the
diagnostic workup of immunocompromised patients.
In vitro susceptibility testing showed that the
fungus had low MICs of amphotericin B, posacona-
zole, itraconazole, voriconazole, isavuconazole,
anidulafungin, and micafungin. Fluconazole was the
least active. The CDC recommends 2 weeks of
intravenous liposomal amphotericin B (3–5 mg/kg
body weight) for T. marneffei infections and then oral
itraconazole (400 mg qd) for 10 weeks as a standard
treatment for an HIV-infected patient [25]. In conclu-
sion, we report a case of T. marneffei infection in a
HIV-positive patient presumably infected in Southeast
Asia. It is important to consider an infection with T.
marneffei in HIV-infected patients when international
travel to endemic regions is involved.
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